Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04RLX
|
|||
| Former ID |
DCL000295
|
|||
| Drug Name |
Tariquidar
|
|||
| Synonyms |
Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Adrenocortical carcinoma [ICD-11: 2D11.Z; ICD-9: 194] | Discontinued in Phase 2 | [1] | |
| Company |
Xenova Group Ltd.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C38H38N4O6
|
|||
| Canonical SMILES |
COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
|
|||
| InChI |
1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)
|
|||
| InChIKey |
LGGHDPFKSSRQNS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 206873-63-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10249844, 14765736, 46225148, 47207666, 50999244, 53787160, 57346729, 103405029, 103968507, 104418478, 126681115, 128484957, 134338951, 135105769, 137237679, 141638771, 152258253, 160647089, 163409604, 163847876, 164045138, 164194141, 164210141, 170502473, 172919624, 174006280, 185997043, 189053167, 198936031, 203088352, 206245031, 223376130, 223663816, 223705233, 226478912, 241051533, 242060034, 249868381, 251898691, 251971368, 252073301, 252160605, 252216375, 252448550, 252451619, 252553677
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Multidrug resistance protein 1 (ABCB1) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | ABC transporters | |||
| Bile secretion | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | ABC-family proteins mediated transport | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Abacavir transport and metabolism | ||||
| Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Allograft Rejection | ||||
| Drug Induction of Bile Acid Pathway | ||||
| Codeine and Morphine Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010214) | |||
| REF 2 | Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol.2008 Mar 15;75(6):1302-12. | |||
| REF 3 | The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).ACS Chem Neurosci.2011 Feb 16;2(2):82-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.